These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17560621)

  • 21. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
    Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
    Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
    Sellhorn G; Kraft Z; Caldwell Z; Ellingson K; Mineart C; Seaman MS; Montefiori DC; Lagerquist E; Stamatatos L
    J Virol; 2012 Jan; 86(1):128-42. PubMed ID: 22031951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.
    Liang X; Munshi S; Shendure J; Mark G; Davies ME; Freed DC; Montefiori DC; Shiver JW
    Vaccine; 1999 Jul; 17(22):2862-72. PubMed ID: 10438057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins.
    Sugiura W; Broder CC; Moss B; Earl PL
    Virology; 1999 Feb; 254(2):257-67. PubMed ID: 9986792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
    Gorny MK; Williams C; Volsky B; Revesz K; Wang XH; Burda S; Kimura T; Konings FA; Nádas A; Anyangwe CA; Nyambi P; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2006 Jul; 80(14):6865-72. PubMed ID: 16809292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
    J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    Quiñones-Kochs MI; Buonocore L; Rose JK
    J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.
    Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H
    J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.
    Robinson JE; Franco K; Elliott DH; Maher MJ; Reyna A; Montefiori DC; Zolla-Pazner S; Gorny MK; Kraft Z; Stamatatos L
    J Virol; 2010 Apr; 84(7):3443-53. PubMed ID: 20106929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
    Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
    Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.